Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 145 in homozygous familial hypercholesterolemia
NL-OMON38555Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- Nov 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of evolocumab, sponsored by Amgen. Started Nov 2013; status: active, not recruiting.
02
Drugs
evolocumab
Beyond the preview
Go deeper on NL-OMON38555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38555.